Neoadjuvant

Triple Negative

BRS0092
Phase II
Talazoparib in Neoadjuvant Tx of Germline BRCA1/2 Mutation w/ Early Triple-Neg BreastCancer
PI: Telli
Pending

KEY
Pending
Open for Enrollment
Link
Optional Path
Trial Posting
Extension Study
Immunotherapy
Observational Study
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu